Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Mediators Inflamm ; 2020: 5239419, 2020.
Article in English | MEDLINE | ID: mdl-33414685

ABSTRACT

Breast cancer results from a complex interplay of genetics and environment that alters immune and inflammatory systems to promote tumorigenesis. Obesity and cigarette smoking are well-known risk factors associated breast cancer development. Nicotine known to decrease inflammatory signals also modulates immune responses that favor breast cancer development. However, the mechanisms by which nicotine and obesity contribute to breast cancer remain poorly understood. In this study, we examined potential mechanisms by which nicotine (NIC) and high-fat diet (HFD) promote growth of HCC70 and HCC1806 xenografts from African American (AA) triple negative (TN) breast cancer cells. Immunodeficient mice fed on HFD and treated with NIC generated larger HCC70 and HCC1806 tumors when compared to NIC or HFD alone. Increased xenograft growth in the presence of NIC and HFD was accompanied by higher levels of tissue-resident macrophage markers and anti-inflammatory cytokines including IL4, IL13, and IL10. We further validated the involvement of these players by in vitro and ex vivo experiments. We found a proinflammatory milieu with increased expression of IL6 and IL12 in xenografts with HFD. In addition, nicotine or nicotine plus HFD increased a subset of mammary cancer stem cells (MCSCs) and key adipose browning markers CD137 and TMEM26. Interestingly, there was upregulation of stress-induced pp38 MAPK and pERK1/2 in xenografts exposed to HFD alone or nicotine plus HFD. Scratch-wound assay showed marked reduction in proliferation/migration of nicotine and palmitate-treated breast cancer cells with mecamylamine (MEC), a nicotine acetylcholine receptor (nAchR) antagonist. Furthermore, xenograft development in immune-deficient mice, fed HFD plus nicotine, was reduced upon cotreatment with MEC and SB 203580, a pp38MAPK inhibitor. Our study demonstrates the presence of nicotine and HFD in facilitating an anti-inflammatory tumor microenvironment that influences breast tumor growth. This study also shows potential efficacy of combination therapy in obese breast cancer patients who smoke.


Subject(s)
Animal Feed , Anti-Inflammatory Agents/pharmacology , Breast Neoplasms/chemically induced , Diet, High-Fat , Nicotine/pharmacology , Animals , Cell Line, Tumor , Cell Proliferation , Female , Humans , Imidazoles/pharmacology , Inflammasomes , Inflammation , Mammary Neoplasms, Animal/chemically induced , Mammary Neoplasms, Animal/pathology , Mecamylamine/chemistry , Mice , Neoplasm Transplantation , Neoplastic Stem Cells/metabolism , Nicotine/chemistry , Nicotine/metabolism , Oxidative Stress/drug effects , Pyridines/pharmacology , Up-Regulation , p38 Mitogen-Activated Protein Kinases/metabolism
3.
Shock ; 44(2): 188-95, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25895149

ABSTRACT

Sinomenine (SIN), an alkaloid derived from the plant Sinomenium acutum, has anti-inflammatory and analgesic effects and has been used for rheumatoid arthritis treatment in China. This study aims to verify the hypothesis that SIN acts on α7 nicotinic acetylcholine receptor (α7nAChR) to inhibit the activation of macrophages stimulated by lipopolysaccharide. The prototypical α7nAChR antagonist α-bungarotoxin and mecamylamine attenuated the effect of SIN on tumor necrosis factor-α and interleukin-6 in RAW264.7 murine macrophage-like cells and primary peritoneal macrophages of mouse induced by lipopolysaccharide. With the knockdown of α7nAChR expression in RAW264.7 cells by small interfering RNA, the inhibitory effect of SIN on tumor necrosis factor-α and interleukin-6 was reversed. Sinomenine decreased p65 expression in nuclear and increased IκBα expression in cytoplasm, and these effects were reversed by the α7nAChR small interfering RNA as well. These results indicate that the anti-inflammatory effects of SIN on macrophages in vitro depend on α7nAChR.


Subject(s)
Anti-Inflammatory Agents/chemistry , Lipopolysaccharides/chemistry , Macrophages, Peritoneal/drug effects , Morphinans/chemistry , alpha7 Nicotinic Acetylcholine Receptor/metabolism , Animals , Bungarotoxins/chemistry , Cytoplasm/metabolism , I-kappa B Proteins/metabolism , Interleukin-6/metabolism , Macrophages, Peritoneal/metabolism , Male , Mecamylamine/chemistry , Mice , Mice, Inbred BALB C , NF-KappaB Inhibitor alpha , RAW 264.7 Cells , RNA Interference , RNA, Small Interfering/metabolism , Tumor Necrosis Factor-alpha/metabolism
4.
Biochemistry ; 53(5): 908-18, 2014 Feb 11.
Article in English | MEDLINE | ID: mdl-24437521

ABSTRACT

To characterize the binding sites of mecamylamine enantiomers on the transmembrane domain (TMD) of human (h) (α4)3(ß2)2 and (α4)2(ß2)3 nicotinic acetylcholine receptors (AChRs), we used nuclear magnetic resonance (NMR), molecular docking, and radioligand binding approaches. The interactions of (S)-(+)- and (R)-(-)-mecamylamine with several residues, determined by high-resolution NMR, within the hα4ß2-TMD indicate different modes of binding at several luminal (L) and nonluminal (NL) sites. In general, the residues sensitive to each mecamylamine enantiomer are similar at both receptor stoichiometries. However, some differences were observed. The molecular docking experiments were crucial for delineating the location and orientation of each enantiomer in its binding site. In the (α4)2(ß2)3-TMD, (S)-(+)-mecamylamine interacts with the L1 (i.e., between positions -3' and -5') and L2 (i.e., between positions 16' and 20') sites, whereas the ß2-intersubunit (i.e., cytoplasmic end of two ß2-TMDs) and α4/ß2-intersubunit (i.e., cytoplasmic end of α4-TM1 and ß2-TM3) sites are shared by both enantiomers. In the (α4)3(ß2)2-TMD, both enantiomers bind with different orientations to the L1' (closer to ring 2') and α4-intrasubunit (i.e., at the cytoplasmic ends of α4-TM1 and α4-TM2) sites, but only (R)-(-)-mecamylamine interacts with the L2' (i.e., closer to ring 20') and α4-TM3-intrasubunit sites. Our findings are important because they provide, for the first time, a structural understanding of the allosteric modulation elicited by mecamylamine enantiomers at each hα4ß2 stoichiometry. This advancement could be beneficial for the development of novel therapies for the treatment of several neurological disorders.


Subject(s)
Mecamylamine/chemistry , Receptors, Nicotinic/chemistry , Allosteric Regulation , Binding Sites , Binding, Competitive , HEK293 Cells , Humans , Magnetic Resonance Spectroscopy , Mecamylamine/metabolism , Molecular Docking Simulation , Protein Structure, Tertiary , Protein Subunits/chemistry , Protein Subunits/metabolism , Receptors, Nicotinic/metabolism , Stereoisomerism
5.
Eur J Pharmacol ; 720(1-3): 264-75, 2013 Nov 15.
Article in English | MEDLINE | ID: mdl-24161916

ABSTRACT

A previous characterization of mecamylamine stereoisomers using nicotinic acetylcholine receptors expressed in Xenopus oocytes revealed only small differences between the activity of the R and S forms of mecamylamine. However, that work was limited in the breadth of receptor subtypes tested, especially in regard to the discrimination of high and low sensitivity receptors, which differ in the ratios of alpha and beta subunits. We report new data using subunit concatamers, which produce uniform populations of high-sensitivity or low-sensitivity receptors, as well as alpha2, alpha5, and alpha6-containing receptors, which were not studied previously. Consistent with previous studies, we found that beta4-containing receptors were most sensitive to mecamylamine and that the IC50 values for the inhibition of net charge were lower than for inhibition of peak currents. No large differences were seen between the activities of the mecamylamine isomers. Additionally, a previously reported potentiation of high-sensitivity α4ß2 receptors by S-mecamylamine could not be reproduced in the oocyte system, even with mutants that had greatly reduced sensitivity to mecamylamine inhibition or when the selective agonist TC-2559 was used. In vivo studies suggested that the R-isomer might be somewhat more potent than the S isomer at blocking CNS effects of nicotine. Although the potency difference was no more than a factor of two, it is consistent with lower LD50 estimates previously reported for the R isomer. Our results significantly extend knowledge of the nicotinic acetylcholine receptor activity profile of mecamylamine and support the hypothesis that these effects are not strongly stereoisomer selective.


Subject(s)
Mecamylamine/pharmacology , Nicotinic Antagonists/pharmacology , Receptors, Nicotinic/physiology , Analgesics/chemistry , Analgesics/pharmacology , Analgesics/therapeutic use , Animals , Hot Temperature , Humans , Male , Mecamylamine/chemistry , Mecamylamine/therapeutic use , Mice , Mice, Inbred ICR , Nicotinic Antagonists/chemistry , Nicotinic Antagonists/therapeutic use , Oocytes/physiology , Pain/drug therapy , Protein Subunits/physiology , Stereoisomerism , Xenopus laevis
6.
Pharmacol Biochem Behav ; 108: 28-43, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23603417

ABSTRACT

Mecamylamine (3-methylaminoisocamphane hydrochloride) is a nicotinic parasympathetic ganglionic blocker, originally utilized as a therapeutic agent to treat hypertension. Mecamylamine administration produces several deleterious side effects at therapeutically relevant doses. As such, mecamylamine's use as an antihypertensive agent was phased out, except in severe hypertension. Mecamylamine easily traverses the blood-brain barrier to reach the central nervous system (CNS), where it acts as a nicotinic acetylcholine receptor (nAChR) antagonist, inhibiting all known nAChR subtypes. Since nAChRs play a major role in numerous physiological and pathological processes, it is not surprising that mecamylamine has been evaluated for its potential therapeutic effects in a wide variety of CNS disorders, including addiction. Importantly, mecamylamine produces its therapeutic effects on the CNS at doses 3-fold lower than those used to treat hypertension, which diminishes the probability of peripheral side effects. This review focuses on the pharmacological properties of mecamylamine, the differential effects of its stereoisomers, S(+)- and R(-)-mecamylamine, and the potential for effectiveness in treating CNS disorders, including nicotine and alcohol addiction, mood disorders, cognitive impairment and attention deficit hyperactivity disorder.


Subject(s)
Mecamylamine/therapeutic use , Nicotinic Antagonists/therapeutic use , Animals , Drug Evaluation, Preclinical , Humans , Mecamylamine/chemistry , Nicotinic Antagonists/chemistry , Stereoisomerism
7.
Int J Biochem Cell Biol ; 42(6): 1007-18, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20223294

ABSTRACT

The interaction of tricyclic antidepressants with the human (h) alpha4beta2 nicotinic acetylcholine receptor in different conformational states was compared with that for the noncompetitive antagonist mecamylamine by using functional and structural approaches. The results established that: (a) [(3)H]imipramine binds to halpha4beta2 receptors with relatively high affinity (K(d)=0.83+/-0.08 microM), but imipramine does not differentiate between the desensitized and resting states, (b) although tricyclic antidepressants inhibit (+/-)-epibatidine-induced Ca(2+) influx in HEK293-halpha4beta2 cells with potencies that are in the same concentration range as that for (+/-)-mecamylamine, tricyclic antidepressants inhibit [(3)H]imipramine binding to halpha4beta2 receptors with affinities >100-fold higher than that for (+/-)-mecamylamine. This can be explained by our docking results where imipramine interacts with the leucine (position 9') and valine (position 13') rings by van der Waals contacts, whereas mecamylamine interacts electrostatically with the outer ring (position 20'), (c) van der Waals interactions are in agreement with the thermodynamic results, indicating that imipramine interacts with the desensitized and resting receptors by a combination of enthalpic and entropic components. However, the entropic component is more important in the desensitized state, suggesting local conformational changes. In conclusion, our data indicate that tricyclic antidepressants and mecamylamine efficiently inhibit the ion channel by interacting at different luminal sites. The high proportion of protonated mecamylamine calculated at physiological pH suggests that this drug can be attracted to the channel mouth before binding deeper within the receptor ion channel finally blocking ion flux.


Subject(s)
Antidepressive Agents, Tricyclic/metabolism , Imipramine/metabolism , Ion Channels/metabolism , Mecamylamine/metabolism , Nicotinic Antagonists/metabolism , Receptors, Nicotinic/metabolism , Antidepressive Agents, Tricyclic/chemistry , Antidepressive Agents, Tricyclic/pharmacology , Binding Sites , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Calcium Signaling/drug effects , Cell Line , Humans , Imipramine/chemistry , Imipramine/pharmacology , Ion Channels/chemistry , Ion Channels/genetics , Mecamylamine/chemistry , Mecamylamine/pharmacology , Nicotinic Antagonists/chemistry , Nicotinic Antagonists/pharmacology , Protein Binding , Protein Conformation/drug effects , Pyridines/pharmacology , Receptors, Nicotinic/chemistry , Receptors, Nicotinic/genetics
9.
J Pharmacol Exp Ther ; 328(2): 525-32, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18957576

ABSTRACT

(+/-)-Mecamylamine is a racemic mixture of a widely used brain-permeant noncompetitive inhibitor of muscle-type and neuronal nicotinic receptors (NNRs). The present studies evaluated whether the stereoisomers of this drug show different profiles for inhibition of the high-sensitivity (HS) and low-sensitivity (LS) isoforms of the human alpha4beta2 NNR subtype expressed in subclonal human epithelial 1 cells. We found that at low concentrations (micromolar range), TC-5214 [S-(+)-mecamylamine] was more effective than TC-5213 [R-(-)-mecamylamine] in inhibiting the LS alpha4beta2 NNRs. In addition, we demonstrated that TC-5214 potentiated and TC-5213 inhibited agonist-induced activation of HS alpha4beta2 NNRs. The stereoselectivity of mecamylamine enantiomers at HS and LS alpha4beta2 receptors demonstrates that TC-5214 is the preferred stereoisomer for selective activation of HS, whereas it is more effective in suppressing LS receptor function. This feature could be relevant to therapeutic applications where such a selective mechanism of action is required.


Subject(s)
Allosteric Regulation/drug effects , Mecamylamine/pharmacology , Receptors, Nicotinic/drug effects , Allosteric Regulation/physiology , Biophysical Phenomena/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Epithelial Cells , Humans , Mecamylamine/chemistry , Muscles/cytology , Muscles/drug effects , Muscles/metabolism , Neurons/drug effects , Neurons/metabolism , Receptors, Nicotinic/metabolism , Stereoisomerism
10.
Anal Chem ; 77(3): 895-901, 2005 Feb 01.
Article in English | MEDLINE | ID: mdl-15679359

ABSTRACT

Four affinity chromatography stationary phases have been developed based upon immobilized nicotinic acetylcholine receptor (nAChR) subtypes, the alpha3beta2, alpha3beta4, alpha4beta2, and alpha4beta4 nAChRs. The stationary phases were created using membranes from cell lines expressing the subtypes and an immobilized artificial membrane stationary phase. The immobilized nAChRs were characterized using frontal chromatography with the agonist epibatidine as the marker. The observed binding affinities for the agonists epibatidine, nicotine, and cytisine were consistent with reported values, indicating that the nAChRs retained their ability to bind agonists. The noncompetitive inhibitors (NCIs) of the nAChR (R)- and (S)-mecamylamine, phencylcidine, dextromethoprphan, and levomethorphan were also chromatographed on the columns using nonlinear chromatography techniques. The studies were carried out before and after exposure of the columns to epibatidine. The NCI retention times increased after exposure to epibtatidine as did the enantioselective separation of mecamylamine and methorphan. The results indicate that the immobilized nAChRs retained their ability to undergo agonist-induced conformational change from the resting to the desensitized states. The columns provide a unique ability to study the interactions of NCIs with both of these conformational states.


Subject(s)
Chromatography, Liquid/methods , Receptors, Nicotinic/chemistry , Alkaloids/chemistry , Azocines/chemistry , Binding, Competitive , Biomarkers , Bridged Bicyclo Compounds, Heterocyclic/chemistry , Cell Line , Chromatography, Affinity , Dextromethorphan/chemistry , Mecamylamine/chemistry , Membranes, Artificial , Nicotine/chemistry , Nicotinic Agonists/chemistry , Nicotinic Agonists/pharmacology , Nicotinic Antagonists/chemistry , Nicotinic Antagonists/pharmacology , Phencyclidine/chemistry , Protein Conformation , Pyridines/chemistry , Quinolizines/chemistry , Receptors, Nicotinic/drug effects
11.
Life Sci ; 69(22): 2583-91, 2001 Oct 19.
Article in English | MEDLINE | ID: mdl-11712662

ABSTRACT

Recent genetic research has shown that certain forms of epilepsy may arise from mutations in the genes encoding for the alpha7 and alpha4 neuronal nicotinic acetylcholine receptor (nAChR) ion channels. These receptors are also involved with the induction of nicotine-induced seizures. (+/-)-Mecamylamine (Inversine), a classic nAChR antagonist, potently inhibits nicotine-induced seizures. The purpose of the present study was to assess the inhibitory effects of (+/-)-mecamylamine and its stereoisomers on nicotine-induced seizures in male Sprague-Dawley rats. Rats received saline, (+/-)-mecamylamine, R-(-)-mecamylamine, or S-(+)-mecamylamine (s.c.) at doses of 0.1, 0.3, or 1.0 mg/kg 15 minutes prior to nicotine injection, 3.6 mg/kg (s.c.), an optimal dose for seizure induction. Rats were observed for 30 minutes with seizure latency, duration, and severity as primary measures and locomotor activity recorded as a secondary measure at 5-minute intervals. The results indicate that mecamylamine and each of its stereoisomers block nicotine-induced seizures in a dose-related manner and suggest that the S-(+/-)- mecamylamine isomer has inhibitory properties more similar to the racemic than to the R-(-)-mecamylamine isomer. The results of this study may be clinically important for the future design of novel anti-seizure medications.


Subject(s)
Mecamylamine/therapeutic use , Nicotinic Antagonists/therapeutic use , Seizures/prevention & control , Animals , Disease Models, Animal , Male , Mecamylamine/administration & dosage , Mecamylamine/chemistry , Molecular Conformation , Nicotine , Nicotinic Antagonists/administration & dosage , Nicotinic Antagonists/chemistry , Rats , Rats, Sprague-Dawley , Seizures/chemically induced
12.
J Pharmacol Exp Ther ; 297(2): 646-56, 2001 May.
Article in English | MEDLINE | ID: mdl-11303054

ABSTRACT

Because mecamylamine, a nicotinic receptor antagonist, is used so often in nicotine research and because mecamylamine may have important therapeutic properties clinically, it is important to fully explore and understand its pharmacology. In the present study, the efficacy and potency of mecamylamine and its stereoisomers were evaluated as inhibitors of human alpha 3 beta 4, alpha 3 beta 2, alpha 7, and alpha 4 beta 2 nicotinic acetylcholine receptors (nAChRs), as well as mouse adult type muscle nAChRs and rat N-methyl-D-aspartate (NMDA) receptors expressed in Xenopus oocytes. The selectivity of mecamylamine for neuronal nAChR was manifested primarily in terms of slow recovery rates from mecamylamine-induced inhibition. Neuronal receptors showed a prolonged inhibition after exposure to low micromolar concentrations of mecamylamine. Muscle-type receptors showed a transient inhibition by similar concentrations of mecamylamine, and NMDA receptors were only transiently inhibited by higher micromolar concentrations. Mecamylamine inhibition of neuronal nAChR was noncompetitive and voltage dependent. Although there was little difference between S-(+)-mecamylamine and R-(-)-mecamylamine in terms of 50% inhibition concentration values for a given receptor subtype, there appeared to be significant differences in the off-rates for the mecamylamine isomers from the receptors. Specifically, S-(+)-mecamylamine appeared to dissociate more slowly from alpha 4 beta 2 and alpha 3 beta 4 receptors than did R-(-)-mecamylamine. In addition, it was found that muscle-type receptors appeared to be somewhat more sensitive to R-(-)-mecamylamine than to S-(+)-mecamylamine. Together, these findings suggest that in chronic (i.e., therapeutic) application, S-(+)-mecamylamine might be preferable to R-(-)-mecamylamine in terms of equilibrium inactivation of neuronal receptors with decreased side effects associated with muscle-type receptors.


Subject(s)
Mecamylamine/pharmacology , Nicotinic Antagonists/pharmacology , Receptors, Nicotinic/drug effects , Animals , Binding, Competitive/drug effects , Electrophysiology , Humans , In Vitro Techniques , Mecamylamine/chemistry , Neurons/drug effects , Nicotinic Antagonists/chemistry , Oocytes/drug effects , Oocytes/metabolism , RNA, Messenger/biosynthesis , Stereoisomerism , Xenopus laevis
SELECTION OF CITATIONS
SEARCH DETAIL
...